PDCD1 and renal carcinoma: In yet another report, An et al. performed a meta-analysis of thirteen pooled studies of NSCLC, melanoma, renal cancer, and other types of cancer patients treated with any of the following ICI agents: anti-PD-1 (pembrolizumab or nivolumab) or anti-PD-L1 (atezolizumab).